Diabetic macular edema: Upcoming therapies

Area of Science:

• Ophthalmology
• Endocrinology
• Pharmacology

Background:

• Diabetic macular edema (DME) is a major cause of vision loss in diabetic retinopathy.
• Current anti-vascular endothelial growth factor (VEGF) treatments are effective but have limitations like frequent injections and resistance.

Purpose of the Study:

• To review emerging and novel therapeutic strategies for diabetic macular edema.
• To highlight advancements beyond conventional anti-VEGF therapies.

Main Methods:

• Literature review of current and emerging treatments for DME.
• Analysis of novel therapeutic classes including WNT agonists, gene therapy, and oral medications.

Main Results:

• Emerging therapies show promise for improved DME management.
• Non-invasive and oral drug options represent a significant advancement.

Conclusions:

• Novel treatments for DME offer potential for better patient outcomes and reduced treatment burden.
• Continued research into evolving therapies is crucial for managing vision loss in diabetic retinopathy.